Sporanox patent ruling
Executive Summary
Trial court's ruling that Eon's generic Sporanox (itraconazole) does not infringe a Janssen patent affirmed by the Federal Circuit June 13. Eon launched its generic in February with 180 days of marketing exclusivity (1"The Pink Sheet" Feb. 14, 2005, In Brief)...
You may also be interested in...
Sporanox generic launches
Eon launches first generic of Janssen's antifungal Sporanox (itraconazole) Feb. 9. Eon, which holds 180-day marketing exclusivity on itraconazole 100 mg capsules, received ANDA approval in May but was barred from launching by a temporary restraining order in Janssen's patent infringement lawsuit (1"The Pink Sheet" June 7, 2004, In Brief). A federal judge ruled in July that Eon's ANDA does not infringe; the case is under appeal. Eon says it timed its launch for the start of the heavy prescribing season for itraconazole...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.